8-K: Serina Therapeutics Sells UniverXome Bioengineering to Juvenescence

Serina Therapeutics divests its subsidiary, UniverXome Bioengineering, to Juvenescence in a deal involving debt assumption and a nominal cash payment.

Summary

• Serina Therapeutics, Inc. has sold its wholly-owned subsidiary, UniverXome Bioengineering, Inc., to JuvVentures (UK) Limited, a subsidiary of Juvenescence.
• The sale was completed on December 23, 2024, with Juvenescence assuming approximately $11.2 million of secured debt owed by UniverXome and making a nominal cash payment.
• UniverXome was initially formed by AgeX Therapeutics in August 2023 and held assets including interests in ReCyte Therapeutics and Reverse Bioengineering.
• The assets transferred to UniverXome included intellectual property, biological materials, trademarks, equipment, and records.
• UniverXome owns 94.8% of ReCyte, which focuses on stem cell-derived treatments for vascular disorders, and 100% of Reverse Bio, which is involved in cellular reprogramming technology.
• The transaction was approved by a special committee of Serina's board of directors, which obtained an independent third-party valuation of UniverXome's assets.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company divested an asset for a nominal price, it also removed debt from its balance sheet. The transaction was approved by a special committee, which adds a layer of confidence. However, the related party nature of the deal and the lack of perfection of the intellectual property transfer temper the positive sentiment.

Positives

• Serina Therapeutics has divested a non-core asset, potentially streamlining its operations.
• The transaction allows Serina to remove approximately $11.2 million in debt from its balance sheet.
• The sale was approved by an independent special committee, ensuring a fair process.
• The deal provides a clean break from the UniverXome assets and liabilities.

Negatives

• Serina received only a nominal cash payment for the sale of UniverXome.
• The assets sold were encumbered by debt, limiting their value to Serina.
• Serina has limited knowledge of the assets of UniverXome and has made no warranties regarding them.
• The transfer of intellectual property to UniverXome was not perfected, requiring future action by the buyer.

Risks

• The buyer, Juvenescence, is a related party, which could raise concerns about the fairness of the transaction.
• The intellectual property transfer was not perfected, which could lead to future complications and costs for the buyer.
• Serina has limited knowledge of the assets of UniverXome, which could lead to unforeseen issues for the buyer.
• The assets of UniverXome are encumbered by debt, which could impact their future value.

Future Outlook

The document does not contain specific forward-looking statements regarding Serina's future performance, but it does outline the completion of the sale of UniverXome and the associated debt removal.

Management Comments

• The Special Committee approved the execution and delivery by the Company of the Stock Purchase Agreement and the related transactions.
• Seller has limited knowledge of and experience with the assets of the Company and thus has made no representation or warranty, express or implied, with respect to the assets of the Company except as expressly set forth herein.

Industry Context

This transaction reflects a strategic move by Serina to divest non-core assets, which is a common practice in the biotechnology industry to focus on core competencies and improve financial health. The sale to a related party, Juvenescence, is not uncommon in the industry, especially when a company is seeking to streamline its operations.

Comparison to Industry Standards

• The sale of a subsidiary for a nominal cash payment and the assumption of debt is not uncommon in situations where the subsidiary's assets are encumbered or not considered core to the parent company's strategy.
• The use of a special committee to evaluate and approve the transaction is a standard practice to ensure fairness and transparency in related-party transactions.
• The level of detail in the agreement, including the disclaimers of warranties and the mutual releases, is typical for transactions of this nature.
• The transaction is similar to other divestitures in the biotech industry where companies sell off non-core assets to focus on their primary research and development activities.

Management Changes

Related Party Transactions

• The buyer, JuvVentures (UK) Limited, is a subsidiary of Juvenescence, which is the largest holder of Serina's common stock and has representatives on Serina's board of directors.
• The transaction was approved by a special committee of independent directors to address potential conflicts of interest.

Stakeholder Impact

• Shareholders may view the sale as a positive step towards streamlining operations and reducing debt.
• Employees of UniverXome, ReCyte, and Reverse Bio will now be under the ownership of Juvenescence.
• Creditors of UniverXome will now have Juvenescence as the primary debtor.

Next Steps

• The buyer, Juvenescence, will need to perfect the transfer of intellectual property assets.
• The buyer will assume control of UniverXome, ReCyte, and Reverse Bio.
• Serina will continue to operate as a separate entity, focusing on its core business.

Key Dates

Keywords

Serina Therapeutics, Juvenescence, UniverXome Bioengineering, asset sale, debt assumption, ReCyte Therapeutics, Reverse Bioengineering, intellectual property, special committee, related party transaction